Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
5
ATAI Quote, Financials, Valuation and Earnings
Last price:
$1.21
Seasonality move
:
-19.09%
Day range:
$1.15 - $1.26
52-week range:
$1.03 - $2.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.37x
Volume:
2.5M
Avg. volume:
2M
1-year change:
-9.85%
Market cap:
$199.7M
Revenue:
$314K
EPS (TTM):
-$0.80
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$0.16 | 1288.89% | -36.36% | -- |
|
AFMD
Affimed NV
|
$1.5M | -$1.06 | -50.03% | -42.4% | $18.90 |
|
BNTX
BioNTech SE
|
$561.1M | -$1.75 | -24.68% | -74.38% | $137.54 |
|
CVAC
CureVac NV
|
$150.6M | $1.54 | -66% | -69.73% | $7.38 |
|
IFRX
InflaRx NV
|
$84.1K | -$0.27 | 5602.11% | -2.23% | $8.04 |
|
IMTX
Immatics NV
|
$17.4M | -$0.28 | -11.96% | -3.68% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
$1.19 | -- | $199.7M | -- | $0.00 | 0% | -- |
|
AFMD
Affimed NV
|
$1.18 | $18.90 | $19.3M | -- | $0.00 | 0% | 19.11x |
|
BNTX
BioNTech SE
|
$113.08 | $137.54 | $27.1B | 184.86x | $0.00 | 0% | 8.26x |
|
CVAC
CureVac NV
|
$2.89 | $7.38 | $647.2M | 5.26x | $0.00 | 0% | 1.09x |
|
IFRX
InflaRx NV
|
$2.25 | $8.04 | $132.2M | -- | $0.00 | 0% | 716.25x |
|
IMTX
Immatics NV
|
$6.85 | -- | $832.6M | -- | $0.00 | 0% | 5.50x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
13.5% | 2.808 | 11.65% | 4.73x |
|
AFMD
Affimed NV
|
31.93% | 0.815 | 16.35% | 1.76x |
|
BNTX
BioNTech SE
|
1.26% | 0.543 | 0.96% | 7.10x |
|
CVAC
CureVac NV
|
-- | 2.309 | -- | 6.10x |
|
IFRX
InflaRx NV
|
-- | 4.286 | -- | 4.34x |
|
IMTX
Immatics NV
|
-- | 1.740 | -- | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATAI
ATAI Life Sciences NV
|
-- | -$22.6M | -56.15% | -61.19% | -64200% | -$19.3M |
|
AFMD
Affimed NV
|
-- | -$15.7M | -127.62% | -158.94% | -9594.22% | -$13.2M |
|
BNTX
BioNTech SE
|
$1.2B | $11.5M | -2.32% | -2.35% | 13.39% | -$770.2M |
|
CVAC
CureVac NV
|
$519.1M | $404.1M | 21.3% | 21.3% | 75.06% | $381.2M |
|
IFRX
InflaRx NV
|
$216K | -$16.9M | -61.55% | -61.55% | -14084.63% | -$11.2M |
|
IMTX
Immatics NV
|
-- | $565.3K | -16.88% | -16.88% | -4.19% | -$42M |
ATAI Life Sciences NV vs. Competitors
-
Which has Higher Returns ATAI or AFMD?
Affimed NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -9767.12%. ATAI Life Sciences NV's return on equity of -61.19% beat Affimed NV's return on equity of -158.94%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.16 $169.1M AFMDAffimed NV-- -$1.03 $28.2M -
What do Analysts Say About ATAI or AFMD?
ATAI Life Sciences NV has a consensus price target of --, signalling upside risk potential of 572.27%. On the other hand Affimed NV has an analysts' consensus of $18.90 which suggests that it could grow by 1499.1%. Given that Affimed NV has higher upside potential than ATAI Life Sciences NV, analysts believe Affimed NV is more attractive than ATAI Life Sciences NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV0 0 0 AFMDAffimed NV5 1 0 -
Is ATAI or AFMD More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Affimed NV has a beta of 2.063, suggesting its more volatile than the S&P 500 by 106.315%.
-
Which is a Better Dividend Stock ATAI or AFMD?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Affimed NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Affimed NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or AFMD?
ATAI Life Sciences NV quarterly revenues are $40K, which are smaller than Affimed NV quarterly revenues of $170.5K. ATAI Life Sciences NV's net income of -$26.3M is lower than Affimed NV's net income of -$16.7M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Affimed NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is -- versus 19.11x for Affimed NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV-- -- $40K -$26.3M AFMDAffimed NV19.11x -- $170.5K -$16.7M
-
Which has Higher Returns ATAI or BNTX?
BioNTech SE has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 15.91%. ATAI Life Sciences NV's return on equity of -61.19% beat BioNTech SE's return on equity of -2.35%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.16 $169.1M BNTXBioNTech SE85.63% $0.89 $21.6B -
What do Analysts Say About ATAI or BNTX?
ATAI Life Sciences NV has a consensus price target of --, signalling upside risk potential of 572.27%. On the other hand BioNTech SE has an analysts' consensus of $137.54 which suggests that it could grow by 21.63%. Given that ATAI Life Sciences NV has higher upside potential than BioNTech SE, analysts believe ATAI Life Sciences NV is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV0 0 0 BNTXBioNTech SE11 5 0 -
Is ATAI or BNTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioNTech SE has a beta of 0.217, suggesting its less volatile than the S&P 500 by 78.349%.
-
Which is a Better Dividend Stock ATAI or BNTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or BNTX?
ATAI Life Sciences NV quarterly revenues are $40K, which are smaller than BioNTech SE quarterly revenues of $1.4B. ATAI Life Sciences NV's net income of -$26.3M is lower than BioNTech SE's net income of $217.9M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 184.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is -- versus 8.26x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV-- -- $40K -$26.3M BNTXBioNTech SE8.26x 184.86x $1.4B $217.9M
-
Which has Higher Returns ATAI or CVAC?
CureVac NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of 68.44%. ATAI Life Sciences NV's return on equity of -61.19% beat CureVac NV's return on equity of 21.3%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.16 $169.1M CVACCureVac NV95.56% $1.65 $809.4M -
What do Analysts Say About ATAI or CVAC?
ATAI Life Sciences NV has a consensus price target of --, signalling upside risk potential of 572.27%. On the other hand CureVac NV has an analysts' consensus of $7.38 which suggests that it could grow by 153.19%. Given that ATAI Life Sciences NV has higher upside potential than CureVac NV, analysts believe ATAI Life Sciences NV is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV0 0 0 CVACCureVac NV3 4 0 -
Is ATAI or CVAC More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CureVac NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ATAI or CVAC?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or CVAC?
ATAI Life Sciences NV quarterly revenues are $40K, which are smaller than CureVac NV quarterly revenues of $543.2M. ATAI Life Sciences NV's net income of -$26.3M is lower than CureVac NV's net income of $371.8M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while CureVac NV's PE ratio is 5.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is -- versus 1.09x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV-- -- $40K -$26.3M CVACCureVac NV1.09x 5.26x $543.2M $371.8M
-
Which has Higher Returns ATAI or IFRX?
InflaRx NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -14092.9%. ATAI Life Sciences NV's return on equity of -61.19% beat InflaRx NV's return on equity of -61.55%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.16 $169.1M IFRXInflaRx NV-5376.61% -$0.33 $72.9M -
What do Analysts Say About ATAI or IFRX?
ATAI Life Sciences NV has a consensus price target of --, signalling upside risk potential of 572.27%. On the other hand InflaRx NV has an analysts' consensus of $8.04 which suggests that it could grow by 258.31%. Given that ATAI Life Sciences NV has higher upside potential than InflaRx NV, analysts believe ATAI Life Sciences NV is more attractive than InflaRx NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV0 0 0 IFRXInflaRx NV3 1 0 -
Is ATAI or IFRX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.534%.
-
Which is a Better Dividend Stock ATAI or IFRX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IFRX?
ATAI Life Sciences NV quarterly revenues are $40K, which are smaller than InflaRx NV quarterly revenues of $136.2K. ATAI Life Sciences NV's net income of -$26.3M is lower than InflaRx NV's net income of -$19.2M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is -- versus 716.25x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV-- -- $40K -$26.3M IFRXInflaRx NV716.25x -- $136.2K -$19.2M
-
Which has Higher Returns ATAI or IMTX?
Immatics NV has a net margin of -65715% compared to ATAI Life Sciences NV's net margin of -16.95%. ATAI Life Sciences NV's return on equity of -61.19% beat Immatics NV's return on equity of -16.88%.
Company Gross Margin Earnings Per Share Invested Capital ATAIATAI Life Sciences NV-- -$0.16 $169.1M IMTXImmatics NV-- -$0.12 $427.2M -
What do Analysts Say About ATAI or IMTX?
ATAI Life Sciences NV has a consensus price target of --, signalling upside risk potential of 572.27%. On the other hand Immatics NV has an analysts' consensus of -- which suggests that it could grow by 144.53%. Given that ATAI Life Sciences NV has higher upside potential than Immatics NV, analysts believe ATAI Life Sciences NV is more attractive than Immatics NV.
Company Buy Ratings Hold Ratings Sell Ratings ATAIATAI Life Sciences NV0 0 0 IMTXImmatics NV6 0 0 -
Is ATAI or IMTX More Risky?
ATAI Life Sciences NV has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 0.743, suggesting its less volatile than the S&P 500 by 25.688%.
-
Which is a Better Dividend Stock ATAI or IMTX?
ATAI Life Sciences NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ATAI Life Sciences NV pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATAI or IMTX?
ATAI Life Sciences NV quarterly revenues are $40K, which are smaller than Immatics NV quarterly revenues of $55.6M. ATAI Life Sciences NV's net income of -$26.3M is lower than Immatics NV's net income of -$9.4M. Notably, ATAI Life Sciences NV's price-to-earnings ratio is -- while Immatics NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ATAI Life Sciences NV is -- versus 5.50x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATAIATAI Life Sciences NV-- -- $40K -$26.3M IMTXImmatics NV5.50x -- $55.6M -$9.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
